Examining immune-related molecules for the discovery of potential therapeutic targets in non-small cell lung cancers through the analysis of fresh peripheral blood and/or pleural effusion from patients treated with anti-PD-1 antibodies.
- Conditions
- Previously treated patients with non-small cell lung cancer
- Registration Number
- JPRN-UMIN000024623
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Prospective immune-profiling using fresh whole blood still on going. In follow-up study after discontinuation of anti-PD-1 treatment, we monitored anti PD-1 antibody binding and immune profiling in T cells until complete loss of residual therapeutic antibody binding. We reported the partial results at IASLC meeting 2017(https://www.sciencedirect.com/science/article/pii/S1556086417329428). We completed the recruitment for the follow-up study May 2017.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1)With interstitial pneumonia or pulmonary fibrosis on a chest X-ray 2)Clinically significant drug allergy 3)Presence of other active malignancy 4)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage 5)Positive serum HBs antigen 6)With severe infection, cardiac diseases, diabetes, hypertension, other severe complication 7)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. 8)Pregnancy or lactating patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.